Table 1.
Outcomes of anticoagulation strategies in thrombocytopenic hematologic malignancy patients
| Author (year) | Design | Treatment strategies (n) | Recurrence | Bleeding events | Duration of follow‐up |
|---|---|---|---|---|---|
| Khanal (2016)21, a | Retrospective cohort | Therapeutic LMWH or VKA (15) | 5 | 4 | 24.6 months |
| Prophylactic/reduced LMWH (22) | 3 | 1 | |||
| Campbell (2017)7 | Case series | Therapeutic LMWH or UFH (13) | 1 | 1 | 6 months |
| Li (2017)18 | Retrospective cohort | LMWH/UFH (132) | 2 | 20 | 359 days |
| No anticoagulation (72) | 1 | 10 | |||
| Houghton (2017)17 | Retrospective cohort | Anticoagulation (45) | 1 | 12 | 100 days |
| No anticoagulation (33) | 5 | 1 | |||
| Drakos (1992)16 | Case series | Prophylactic/reduced LMWH (5) | 0 | 0 | NR |
| Lim (2016)15 | Case series | Therapeutic LMWH (1) | 0 | 0 | NR |
| Prophylactic/reduced LMWH (3) | 0 | 2 | |||
| No anticoagulation (1) | 0 | 0 | |||
| Oliver (2015)22 | Retrospective cohort | Therapeutic LMWH (13) | 0 | 5 | 6 months |
| Prophylactic/reduced LMWH (8) | 0 | ||||
| No anticoagulation (14) | 0 | 1 | |||
| Imberti (2004)12 | Case series | Therapeutic LMWHb | 0 | 0 | NR |
| Ibrahim (2005)9 | Case series | Prophylactic/reduced LMWH (26) | NR | 6 | NR |
| Schimmer (1998)20 | Retrospective cohort | Therapeutic UFH (10) | NR | 3 | NR |
| Kopolovic (2015)23 | Retrospective cohort | Full anticoagulation (30) | 8 | 2 | 3 months |
| Partial anticoagulation (27) | 12 | 9 | |||
| No anticoagulation (17) | 3 | 2 | |||
| Samuelson (2017)24 | Retrospective cohort | Therapeutic LMWH or UFH (82) | 5 | 33 | 30 days |
LMWH, low‐molecular‐weight heparin; UFH, unfractionated heparin; VKA, vitamin‐K antagonist.
a
Study included patients with platelets >50, only those with platelets <50 included here.
b
LMWH was dose reduced for platelets <20.